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ABSTRACT 
Background.  Mutations in the KRAS oncogene are common in colorectal cancer (CRC). The 
role of KRAS-mutation status as a prognostic factor, however, is unclear. We evaluated the 
relationship between KRAS-mutation status and CRC survival, considering heterogeneity in this 
association by tumor and patient characteristics. 
Methods.  The population-based study included individuals diagnosed with CRC between 1997-
2007 in Western Washington State.  Tumor specimens were tested for KRAS exon 2 mutations, 
the BRAF p.V600E mutation, and microsatellite instability (MSI).  We used Cox regression to 
estimate hazard ratios (HR) and 95% confidence intervals (CI) for the association between 
KRAS-mutation status and disease-specific and overall survival. Stratified analyses were 
conducted by age, sex, tumor site, stage, and MSI.  We conducted additional analyses 
combining KRAS-mutation, BRAF-mutation, and MSI status. 
Results.  Among 1,989 cases, 31% had KRAS-mutated CRC. KRAS-mutated CRC was 
associated with poorer disease-specific survival (HR=1.37, 95% CI: 1.13-1.66). This association 
was not evident in cases who presented with distant-stage CRC. Cases with KRAS-
wildtype/BRAF-wildtype/MSI-high CRC had the most favorable prognosis; those with CRC 
exhibiting a KRAS- or BRAF-mutation and no MSI had the poorest prognosis. Patterns were 
similar for overall survival.   
Conclusion.  KRAS-mutated CRC was associated with statistically significantly poorer survival 
after diagnosis than KRAS-wildtype CRC.  
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INTRODUCTION 
The Kirsten Ras (KRAS) proto-oncogene encodes for a guanosine triphosphate (GTP) / 
guanosine diphosphate (GDP) binding protein downstream of the epidermal growth factor 
receptor (EGFR) in the RAS/RAF/MAPK pathway. Mutations in KRAS are evident in 30-40% of 
colorectal tumors (Andreyev et al, 1998; De Roock et al, 2010a; De Roock et al, 2010b; 
Gnanasampanthan et al, 2001; Hutchins et al, 2011; Imamura et al, 2012; Inoue et al, 2012; Lee 
et al, 2008; Nash et al, 2010; Roth et al, 2010; Samowitz et al, 2000; Wang et al, 2003). Based 
on evidence that the benefits of adjuvant treatment with anti-EGFR chemotherapy for distant-
stage metastatic colorectal cancer (CRC) are limited to patients with KRAS-wildtype disease 
(Bokemeyer et al, 2012; Lin et al, 2011), testing for KRAS mutations is increasingly common in 
clinical practice in order to better direct treatment of CRC (Allegra et al, 2009). Although the role 
of KRAS-mutation status as a predictive biomarker for response to anti-EGFR targeted therapy 
is well supported, the role of KRAS as a prognostic biomarker for CRC survival, independent of 
anti-EGFR therapy, is less clear.  
A number of previous studies have evaluated the relationship between KRAS-mutation 
status and survival after CRC diagnosis (Andreyev et al, 2001; Andreyev et al, 1998; De Roock 
et al, 2010a; Gnanasampanthan et al, 2001; Hutchins et al, 2011; Imamura et al, 2012; Lee et 
al, 2008; Nash et al, 2010; Ogino et al, 2009a; Roth et al, 2010; Samowitz et al, 2000; Wang et 
al, 2003). In the largest study to date, Andreyev et al. reported that the presence of a somatic 
KRAS mutation was associated with statistically significantly poorer disease-free and overall 
survival after CRC diagnosis, but only among patients with Dukes’ C CRC and only among 
those with the KRAS p.G12V mutation (Andreyev et al, 2001). This latter finding was supported 
by results from a recent study in which KRAS codon 12 mutations, particularly the p.G12V 
mutation, but not KRAS codon 13 mutations were associated with poorer survival (Imamura et 
al, 2012). Thus, observed inconsistencies in the literature regarding the association between 
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KRAS-mutation status and CRC survival may be related to differences in the distribution of 
specific KRAS mutations, stage at diagnosis, or other characteristics.  
Correlations between KRAS-mutation status and other tumor characteristics of 
prognostic relevance may further complicate the study of this marker in relation to prognosis.  In 
particular, KRAS-mutated CRC is less likely to exhibit microsatellite instability (MSI) than KRAS-
wildtype CRCs (Hutchins et al, 2011; Imamura et al, 2012; Nash et al, 2010; Ogino et al, 2009a; 
Roth et al, 2010) and is almost never BRAF-mutated (De Roock et al, 2010a; Hutchins et al, 
2011; Imamura et al, 2012; Lee et al, 2008). The presence of high MSI (MSI-H) is associated 
with a more favorable prognosis (Guastadisegni et al, 2010), whereas BRAF-mutated CRC has 
a poorer prognosis than BRAF-wildtype disease (De Roock et al, 2010a; Ogino et al, 2009b; 
Roth et al, 2010). Failure to account for these attributes of KRAS-mutated CRC could thus 
obscure an association between KRAS-mutation status and CRC survival. 
To better understand the relationship between KRAS-mutation status and survival after 
CRC diagnosis, we used data from two concurrent population-based studies of incident invasive 
CRC conducted in Western Washington State.  
 
MATERIALS AND METHODS  
Study Population 
 Details of the population-based study samples have been published elsewhere 
(Newcomb et al, 2007a; Newcomb et al, 2007b).  Briefly, eligible participants included men and 
women diagnosed with invasive CRC between January 1998 and June 2002 who, at the time of 
diagnosis, were aged 20-74 years and resided in King, Pierce, or Snohomish counties in 
Western Washington State. Women who resided in 10 additional Washington counties and were 
diagnosed during the same time period at ages 50-74 years were also eligible. During a second 
phase of study recruitment, we identified eligible participants as men and women with invasive 
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CRC in this 13-county ascertainment area who were diagnosed at ages 18-49 years between 
April 2002 and July 2007. All cases were identified through the Surveillance, Epidemiology, and 
End Results (SEER) cancer registry serving Western Washington State.  Study eligibility was 
limited to English speakers with a publicly available telephone number.  Of 3,585 individuals 
contacted and identified as eligible, 463 (13%) were deceased, 351 (10%) refused participation, 
128 (4%) could not be reached, and 24 (0.7%) completed only a partial interview. In total, 76% 
of eligible cases were enrolled in the study (N=2,708).  
At an average of 8.6 months after diagnosis, participants completed a structured 
telephone interview in which they were asked to provide detailed information on a number of 
potential risk factors, including smoking history, body mass index (BMI), family history of CRC, 
and use of selected medications.  At the conclusion of the interview, participants were asked for 
consent to access diagnostic tumor specimens. Adequate tumor specimens were obtained for 
78% of enrolled participants (N=2,120). 
This study was approved by the Institutional Review Board of the Fred Hutchinson 
Cancer Research Center in accordance with assurances filed with and approved by the U.S. 
Department of Health and Human Services. 
KRAS-mutation testing and additional tumor characterization 
 DNA was extracted from paraffin-embedded formalin-fixed tumor tissue. In cases for 
whom tumor DNA was successfully extracted (N=1,989), the coding sequence of KRAS exon 2 
was amplified (Oliner et al, 2010). Mutations in exon 2 were identified via forward and reverse 
sequencing of amplified tumor DNA (Alsop et al, 2006). Cases for whom KRAS testing failed 
(N=36) or produced equivocal results (N=30) were classified as having unknown KRAS-
mutation status. For quality control purposes, sequencing was also conducted on three cell-line 
controls (one containing the p.G12V mutation, one containing the p.G13D mutation, and one 
wildtype cell line). 
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Tumor specimens were also assayed for BRAF-mutation status and for the presence of 
microsatellite instability (MSI). Tumor DNA was tested for the c.1799T>A (p.V600E) BRAF 
mutation using a fluorescent allele-specific PCR assay as described previously (Buchanan et al, 
2010). With respect to MSI status, testing for cases enrolled in earlier years of recruitment 
(N=1,430) was based on a 10-gene panel assayed in tumor DNA and in DNA extracted from 
normal surrounding tissue (BAT25, BAT26, BAT40, MYCL, D5S346, D17S250, ACTC, D18S55, 
D10S197, and BAT34C4) (Boland et al, 1998; Newcomb et al, 2007b); tumors were classified 
as MSI-H if instability was observed in ≥30% of markers, and as MSS if instability was observed 
in <30% of markers.  For more recently enrolled cases (N=470), MSI status was based on 
immunohistochemistry (IHC) testing of four markers: MLH1, MSH2, MSH6, and PMS2 (Lindor et 
al, 2002; Shia, 2008); cases whose tumor tissue exhibited positive staining for all markers were 
considered MSS, whereas cases negative for at least one marker were considered MSI-H. High 
concordance between IHC and PCR-based MSI testing has been demonstrated elsewhere 
(Cicek et al, 2011). Cases for whom test results were equivocal or for whom testing was not 
completed (N=80) were classified as having unknown MSI status.   
 Information on tumor site and stage at diagnosis was available from SEER. Tumors 
located in the cecum through the splenic flexure were grouped together as proximal colon 
cancers (ICD-O-3 codes C180, C182, C183, C184, and C185) (World Health Organization, 
2000). Tumors located in the descending (C186) and sigmoid colon (C187) were classified as 
distal colon cancer, and tumors in the rectosigmoid junction (C199) and rectum (C209) were 
grouped together as rectal cancer.  Stage at diagnosis was recorded according to SEER 
summary staging conventions (localized-, regional-, distant-stage).  
Survival information 
Vital status was determined via linkage to SEER and the National Death Index.  For 
cases who died during study follow-up, information was obtained on the date and cause of 
7 
 
death, classified according to ICD-10 conventions (World Health Organization, 2007).  Deaths 
with an underlying cause attributed to ICD-10 codes C18.0-C20.0 or C26.0 (i.e., CRC) were 
classified as disease-specific mortality events.  Vital-status linkage was performed periodically, 
with the most recent linkage capturing deaths occurring through September 2010. 
Statistical analysis 
We used Cox proportional hazards regression to evaluate the association between 
KRAS-mutation status and survival after CRC diagnosis. The time axis for analysis was defined 
as days since diagnosis, with left censoring of participants until the date of study enrollment. We 
conducted separate survival analyses for disease-specific survival and overall survival. In all 
analyses, participants still alive at their last vital-status assessment were censored at that date. 
In analyses of disease-specific survival, we also censored persons who died due to causes 
other than CRC at the time of death.  We evaluated associations between KRAS-mutation 
status and survival outcomes in the full cohort and within strata defined by patient 
characteristics (age at diagnosis, sex) and tumor characteristics (tumor site, stage, MSI status).  
In light of the fact that somatic mutations in KRAS and BRAF rarely co-occur (Davies et al, 
2002), and given that BRAF-mutated CRC has been shown to have a poorer prognosis than 
BRAF-wildtype CRC (De Roock et al, 2010a; Ogino et al, 2009b; Roth et al, 2010), we 
conducted separate analyses: 1) in all cases irrespective of BRAF-mutation status; 2) restricted 
to BRAF-wildtype cases; and 3) combining information on KRAS and BRAF mutations to 
evaluate relative differences in survival for cases with a mutation in either versus neither gene.  
We also evaluated relative differences in survival between case groups defined by joint 
KRAS/MSI status, and by joint KRAS/BRAF/MSI status. Lastly, we explored associations 
between different classes of KRAS mutations and survival outcomes, examining associations 
with specific mutations evident in ≥5% of cases, and, more generally, with codon 12 mutations 
and codon 13 mutations separately; differences in codon-specific associations were evaluated 
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via tests for heterogeneity. For all analyses, proportional hazards assumptions were assessed 
by testing for a non-zero slope of the scaled Schoenfeld residuals on ranked failure times 
(Therneau & Grambsch, 2000). 
Regression models included adjustment terms for age (five-year categories), sex, and 
study phase.  We also assessed potential confounding by several patient and tumor 
characteristics: cigarette smoking (never, former, current); BMI two years before diagnosis 
(<25.0, 25.0-29.9, ≥30.0 kilograms / meters2); race (white, non-white); regular use of non-
steroidal anti-inflammatory drugs at baseline (no, yes); family history of CRC in first-degree 
relatives (no, yes); and tumor site (proximal colon, distal colon / rectum). Of these additional 
factors, only cigarette smoking and BMI were retained in our final analytic model as adjustment 
for other variables had minimal impact on effect estimates (<5% change).  
We conducted sensitivity analyses using alternative approaches to assess the potential 
impact of excluding enrolled cases with unknown KRAS-mutation status. Specifically, we 
replicated analyses: 1) including all cases with missing KRAS-mutation status as KRAS-
wildtype; 2) including cases with missing KRAS-mutation status as KRAS-mutated; and 3) using 
multiple imputation for missing KRAS status. The multiple imputation model was based on all 
covariate variables from the multivariate model, as well as family history of CRC, tumor site, 
MSI status, BRAF-mutation status, race, survival time, and the survival outcome of interest 
(Moons et al, 2006; Sterne et al, 2009).  All analyses were conducted in STATA SE version 12.0 
(College Park, Texas). 
 
RESULTS 
Characteristics of the study population are presented in Table 1 by KRAS-mutation 
status. Approximately 31% of cases had KRAS-mutated CRC. Compared to cases with KRAS-
wildtype CRC, cases with KRAS-mutated disease were statistically significantly less likely to 
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have MSI-H or BRAF-mutated CRC (p-value<0.001). There was no statistically significant 
difference in the distribution of age at diagnosis, sex, tumor site, or stage according to KRAS-
mutation status.  Overall, 38% (N=728) of cases died during the study follow-up period 
(mean=6.5 years, range=5.3 months to 13.7 years). Of those cases who died, approximately 
62% (N=449) died due to CRC. 
Multivariate-adjusted analyses of disease-specific survival yielded estimates nearly 
identical to those from unadjusted analyses, and provided evidence of statistically significantly 
poorer survival in cases with KRAS-mutated versus KRAS-wildtype CRC (Table 2) [hazard ratio 
(HR)=1.37, 95% confidence interval (CI): 1.13-1.66]. The magnitude of this association was 
similar when cases with BRAF-mutated disease were excluded or combined with the KRAS-
mutated case group. Interaction terms by age at diagnosis, sex, tumor site, stage, and MSI 
status were not statistically significant (p>0.05); however, point estimates did vary slightly by 
stage and age at diagnosis. In particular, KRAS-mutation status was not associated with 
survival in cases who presented with distant-stage disease (p-interaction by stage=0.07). 
Additionally, KRAS-mutated CRC was associated with statistically significantly poorer disease-
specific survival in cases aged ≥50 years at diagnosis but not in those aged <50 (p-interaction 
by age=0.15). These non-significant differences in the strength of association across stage and 
age strata were diminished in analyses combining cases with BRAF-mutated and KRAS-
mutated CRC. Associations were similar but attenuated in analyses of overall survival (Table 3).   
In analyses considering KRAS in combination with MSI status (Table 4), disease-specific 
and overall survival were statistically significantly more favorable in cases with KRAS-
wildtype/MSI-H CRC (HR=0.35, 95% CI: 0.23-0.55, and HR=0.78, 95% CI: 0.60-1.00, 
respectively) and statistically significantly poorer in cases with KRAS-mutated/MSS CRC 
(HR=1.24, 95% CI: 1.01-1.52, and HR=1.21, 95% CI: 1.02-1.43, respectively) compared to 
cases with KRAS-wildtype/MSS disease.  Results were similar after excluding cases with 
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BRAF-mutated CRC. Patterns of association also changed very little when combining cases 
with KRAS- and/or BRAF-mutated disease: cases with KRAS- and BRAF-wildtype/MSI-H 
disease had the most favorable prognosis, and those with KRAS- or BRAF-mutated/MSS 
disease had the poorest survival.  
Among cases with KRAS-mutated CRC, 75% (N=444) had a mutation in codon 12 and 
22% (N=132) in codon 13 (Supplemental Table 1). Compared to cases with a codon 12 KRAS 
mutation, those with a codon 13 mutation were statistically significantly more likely to have CRC 
located in the proximal colon (54% versus 40%) and to have MSI-H disease (19% vs. 7%). We 
found no statistically significant differences in the association between KRAS-mutation status 
and survival when we evaluated associations with mutated codon 12 versus mutated codon 13 
(p-heterogeneity=0.54 and p-heterogeneity=0.30 for disease-specific and overall survival, 
respectively). The presence of a somatic p.G13D mutation was associated with statistically 
significantly poorer disease-specific (HR=1.48, 95% CI: 1.04-2.04) and overall survival 
(HR=1.38, 95% CI: 1.05-1.81) compared to KRAS-wildtype; neither p.G12D nor p.G12V 
mutations were significantly associated with survival outcomes when evaluated separately 
(Supplemental Table 2).   
Compared to cases with known KRAS-mutation status, enrolled cases with unknown 
KRAS status were younger at diagnosis (median age=52 versus 60 years), more likely to have 
distant-stage disease (20% versus 12%), and had a lower five-year overall survival (65% versus 
74%) (not shown). In sensitivity analyses, we evaluated the effect of missing information on 
KRAS status (N=728, 29%): in analyses based on our primary analytic model with no exclusion 
of BRAF-mutated cases, including all cases with unknown KRAS-mutation status as KRAS-
mutated cases increased point estimates to HR=1.53 (95% CI: 1.13-1.79) for disease-specific 
survival and HR=1.39 (95% CI: 1.23-1.57) for overall survival. When we instead included these 
728 cases as KRAS-wildtype, point estimates fell to HR=1.12 (95% CI: 0.94-1.34) and HR=1.06 
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(95% CI: 0.92-1.23) for disease-specific and overall survival, respectively. Thus, our point 
estimates comparing survival in KRAS-mutated versus KRAS-wildtype cases are subject to 
some uncertainty due to the exclusion of cases with missing KRAS data.  However, when we 
implemented a multiple imputation model to account for missingness in KRAS, our results 
based on the analysis of known and imputed KRAS data indicated statistically significantly 
poorer disease-specific (HR=1.35, 95% CI: 1.12-1.63) and overall survival (HR=1.22, 95% CI: 
1.05-1.42) associated with the presence of a KRAS mutation. 
 
DISCUSSION 
In this large population-based cohort of men and women with incident invasive CRC, the 
presence of a somatic KRAS mutation was associated with statistically significantly poorer 
survival, specifically in those without distant-stage disease. Patients with KRAS-mutated CRC 
whose tumors were also MSS had the poorest prognosis. These patterns of association were 
relatively unchanged when limited to BRAF-wildtype cases and when grouping BRAF-mutated 
and KRAS-mutated cases. Contrary to some previous reports, we did not find the association 
between KRAS-mutation status and survival to be limited to the p.G12V KRAS-mutation specific 
identified mutations. 
Activating mutations in KRAS are among the most common mutations in human cancers 
(Ikediobi et al, 2006). Mutations in KRAS codons 12 and 13 have been shown to result in an 
altered RAS protein with greater resistance to GTPase activity (Al-Mulla et al, 1999; Bollag & 
McCormick, 1995). By remaining in an active GTP-bound state for longer, mutated RAS 
contributes to enhanced cellular growth and proliferation (Al-Mulla et al, 1999), activating the 
RAS/RAF/MAPK and the phosphoinositide 3-kinase-AKT pathways. The relationship between 
constitutive activation of the RAS/RAF/MAPK signaling pathway and CRC prognosis has 
previously also been supported by studies evaluating the association between the BRAF 
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p.V600E activating mutation and CRC survival (De Roock et al, 2010a; Ogino et al, 2009b; Roth 
et al, 2010). Mutations in BRAF and KRAS are both thought to occur early in colorectal 
carcinogenesis, and are rarely observed together. Here we found that only 1% (N=6) of CRC 
cases with a somatic KRAS mutation harbored a BRAF mutation, compared to 18% of KRAS-
wildtype CRC cases; this is consistent with data from The Cancer Genome Atlas (Cerami et al, 
2012) and recent reports from other large studies (Hutchins et al, 2011; Imamura et al, 2012). 
When we combined information on KRAS and BRAF status to compare survival in CRC cases 
with a somatic mutation in at least one versus neither of these genes, we found only modest 
differences from our analyses where BRAF-mutation status was not considered. 
The presence of a somatic KRAS mutation is also inversely associated with the 
presence of MSI (Imamura et al, 2012; Nash et al, 2010; Ogino et al, 2009a). MSI-H CRC is 
known to have a statistically significantly more favorable prognosis than MSS CRC 
(Guastadisegni et al, 2010), and to have a distinct clinicopathology: the distribution of MSI 
follows a clear gradient of decreasing prevalence from the ascending colon to the rectum 
(Yamauchi et al, 2012) and is less prevalent in cases diagnosed at later stages (Nash et al, 
2010; Ogino et al, 2009b). Although we found that the prevalence of MSI was statistically 
significantly lower in KRAS-mutated versus KRAS-wildtype cases, we found no difference in the 
distribution of tumor site or stage at diagnosis according to KRAS status. We also found no 
statistically significant interaction in the association between KRAS-mutation status and survival 
according to MSI status, tumor site, or stage at diagnosis. However, our results did suggest that 
KRAS-mutation status was not associated with survival in cases who presented with distant-
stage disease, as has been suggested by at least two previous studies (Inoue et al, 2012; Nash 
et al, 2010).  Thus, although the prevalence of somatic KRAS mutations does not appear to 
differ by stage at diagnosis, the prognostic role of KRAS may differ by stage. 
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Several studies in the distant-stage, metastatic setting have demonstrated the utility of 
KRAS-mutation status as a predictive marker for response to anti-EGFR therapy (Bokemeyer et 
al, 2012; Lin et al, 2011). In a recent meta-analysis, Lin et al. reported that the presence of a 
KRAS mutation had a positive likelihood ratio of 2.0 (95% CI: 1.45-2.76) for predicting non-
response to anti-EGFR in distant-stage CRC (Lin et al, 2011). However, the role of KRAS as a 
predictive marker has not been demonstrated for less advanced disease: recently published 
findings from a phase III randomized trial of patients with stage III colon cancer indicated no 
benefit in three-year disease-free survival with the addition of cetuximab to standard 
chemotherapy, regardless of KRAS-mutation status (HR=1.21, 95% CI: 0.98-1.49 in KRAS-
wildtype and HR=1.12, 95% CI: 0.86-1.46 in KRAS-mutated) (Alberts et al, 2012). Results from 
that trial did, however, provide support for the role of KRAS-mutation status as a prognostic 
factor, independent of anti-EGFR therapy: three-year disease-free survival ranged from 72-75% 
across treatment arms in participants with KRAS-wildtype disease versus 65-67% in participants 
with KRAS-mutated disease (Alberts et al, 2012). 
Previous studies focused on KRAS-mutation status as a potential prognostic factor have 
been mixed in their findings.  In the largest study of KRAS-mutation status and survival to date, 
the Kirsten Ras Colorectal Cancer Collaborative Group study (RASCAL, N=2,721), Andreyev et 
al. reported statistically significantly poorer overall survival for KRAS-mutated versus KRAS-
wildtype disease at a magnitude similar to that observed here (HR=1.22, 95% CI: 1.07-1.40) 
(Andreyev et al, 1998). The majority of other, smaller studies have also indicated a poorer 
prognosis in patients with KRAS-mutated CRC (De Roock et al, 2010a; Hutchins et al; Imamura 
et al, 2012; Nash et al). Several studies, however, have failed to find an association between 
KRAS and patient outcomes (Gnanasampanthan et al; Lee et al, 2008; Ogino et al, 2009a; 
Ogino et al, 2009b; Roth et al, 2010; Samowitz et al, 2000; Wang et al, 2003). The basis for 
these inconsistencies is unclear, but may be related to limited sample size and differences in 
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the distribution and consideration of other factors, such as age at diagnosis, stage, and MSI 
status.    
Prior studies have also differed in their consideration of specific KRAS mutations in 
relation to CRC survival. In an update of the original RASCAL study (RASCAL II, N=4,268), 
Andreyev et al. found the association between KRAS-mutation status and survival was largely 
confined to the p.G12V mutation (Andreyev et al, 2001). Imamura et al. recently reported a 
similar finding, and found that mutations in KRAS codon 13 were not associated with CRC 
survival (Imamura et al, 2012). Unlike these reports, we did not find a statistically significant 
association between the p.G12V KRAS mutation and prognosis. Although experimental 
evidence has suggested that mutations in KRAS codon 12, particularly p.G12V, confer lower 
GTPase activity (Al-Mulla et al, 1999; Bollag & McCormick, 1995) which may translate to greater 
transforming potential, our data are not consistent with a clear difference in the prognostic 
significance of somatic KRAS mutations by codon. 
Results presented here should be interpreted in the context of study limitations. Only 
limited information on first course of treatment was available and it is possible that treatment 
could have differed according to KRAS-mutation status; however, 95% of cases were diagnosed 
prior to 2006 at a time before KRAS-mutation status might have been used to decide on anti-
EGFR therapy. KRAS-mutation status does not appear to be associated with differential 
response to other chemotherapies (Hutchins et al, 2011; Ogino et al, 2009a; Richman et al, 
2009). Additionally, KRAS-mutation status was not determined for 29% of enrolled cases. 
Although these cases differed from cases with known KRAS-mutation status on several factors 
that could be related to prognosis, we obtained point estimates similar to those in our primary 
analyses in sensitivity analyses using multiple imputation to account for these missing data. 
KRAS-mutation status also could not be determined in cases who were not enrolled in the 
present study due to refusal, death before enrollment, or loss to follow-up. If KRAS-mutated 
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CRC is truly associated with poorer prognosis, the prevalence of KRAS mutations is likely to 
have been higher in those cases who died before they could be enrolled in the study: exclusion 
of deceased cases would thus have attenuated, rather than inflated our estimates of the 
strength of association.   
 Important strengths of the present study include the population-based design and large 
sample size. Our consideration of both MSI and BRAF-mutation status in evaluating the 
relationship between KRAS-mutation status and CRC survival also represents an important 
strength. Here we confirm previous reports that KRAS-mutated CRC is less likely to be MSI-H 
and is very rarely BRAF-mutated. When we evaluated these three markers in combination in 
relation to survival, we found a strong gradient in risk, particularly with respect to disease-
specific survival. Those individuals with CRC that was KRAS-wildtype, BRAF-wildtype, and MSI-
H had the most favorable disease-specific survival; individuals with CRC that was KRAS- or 
BRAF-mutated and MSS experienced a statistically significantly poorer prognosis than other 
case groups defined by combinations of these three markers. These results support the 
prognostic significance of KRAS-mutation status beyond its now established role as a predictive 
marker in distant-stage CRC. 
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TABLE 1.  Study population characteristics by KRAS-mutation status 
 KRAS-
wildtype 
(N=1330) 
KRAS-
mutated 
(N=593) 
p-value*
Age at diagnosis 
   <50 
   50-59 
   60-69 
   70-74 
 
 
346 (26) 
291 (22) 
415 (31) 
278 (21)
 
147 (25) 
143 (24) 
188 (32) 
115 (19)
 
0.65 
Sex 
   Male 
   Female 
 
 
609 (46) 
721 (54)
 
264 (45) 
329 (55)
 
0.61 
Tumor site 
   Proximal colon 
   Distal colon 
   Rectal 
   Unknown 
 
 
505 (39) 
364 (28) 
424 (33) 
37 
 
 
255 (44) 
147 (25) 
183 (31) 
89
 
0.10 
Stage at diagnosis† 
   Localized 
   Regional 
   Distant 
   Unknown 
 
 
553 (42) 
610 (46) 
144 (11) 
23
 
220 (37) 
293 (50) 
75 (13) 
5
 
0.12 
MSI status† 
   MSS/MSI-L 
   MSI-H 
   Unknown 
 
 
1042 (82) 
236 (18) 
52
 
509 (90) 
56 (10) 
28 
 
 
<0.001 
BRAF mutation status† 
   Wildtype 
   Mutated 
   Unknown 
 
 
1083 (82) 
232 (18) 
15
 
580 (99) 
6 (1) 
7
 
<0.001 
Vital status 
   Alive 
   Deceased 
 
 
843 (63) 
487 (37)
 
352 (59) 
241 (41)
 
0.09 
Mean years of follow-up (SD) 
 
6.7 (3.9) 6.3 (4.1)  
* p-value for chi-square.  
† % distribution excludes cases with unknown value of characteristic 
TABLE 2.  KRAS-mutation status and disease-specific survival after colorectal cancer diagnosis by patient and tumor characteristics, 
with and without consideration of BRAF-mutation status 
  All cases BRAF-wildtype CRC only Joint KRAS / BRAF mutation status
  KRAS  
wildtype 
Deaths / 
Cases 
KRAS  
mutated
Deaths / 
Cases 
 
HR (95% CI)* 
KRAS  
wildtype
Deaths /
Cases 
KRAS 
mutated 
Deaths / 
Cases 
 
HR (95% CI)* 
 
KRAS & 
BRAF wt
Deaths / 
Cases 
 
KRAS or 
BRAF mut
Deaths / 
Cases 
 
HR (95% CI)* 
Overall (unadjusted) 287/1330 162/593 1.36 (1.12-1.65) 238/1098 161/587 1.39 (1.14-1.70) 234/1083 214/834 1.31 (1.09-1.58)
Overall (adjusted) 
 
287/1330 162/593 1.37 (1.13-1.66) 238/1098 161/587 1.40 (1.14-1.72) 234/1083 214/834 1.34 (1.11-1.63)
By age at 
diagnosis: 
<50 years 79/346 34/147 1.03 (0.69-1.54) 67/320 34/147 1.14 (0.76-1.73) 65/317 48/176 1.40 (0.96-2.03)
≥50 years 
 
 
208/984 128/446 1.48 (1.18-1.85) 171/778 127/440 1.49 (1.18-1.88) 169/766 166/658 1.33 (1.07-1.66)
By sex: Male 134/609 74/264 1.35 (1.02-1.79) 119/545 73/261 1.37 (1.03-1.85) 118/542 89/329 1.36 (1.03-1.79)
Female 
 
153/721 88/329 1.38 (1.06-1.81) 119/553 88/326 1.43 (1.07-1.89) 116/541 125/505 1.35 (1.04-1.75)
By tumor site: Proximal 104/505 72/255 1.44 (1.06-1.95) 68/322 71/252 1.45 (1.04-2.04) 67/315 109/444 1.25 (0.92-1.71)
Distal / rectal 
 
178/788 87/330 1.29 (1.00-1.68) 166/745 87/327 1.33 (1.02-1.73) 163/737 101/376 1.35 (1.04-1.73)
By stage at 
diagnosis: 
Localized 29/553 19/220 1.55 (0.85-2.82) 28/463 19/216 1.38 (0.75-2.54) 28/458 20/311 1.06 (0.58-1.93)
Regional 146/610 83/293 1.35 (1.03-1.78) 111/487 82/291 1.47 (1.10-1.96) 109/480 121/424 1.50 (1.15-1.96)
Distant 
 
111/144 59/75 1.02 (0.73-1.41) 98/129 59/75 1.06 (0.76-1.49) 96/126 72/90 1.11 (0.80-1.53)
By MSI: MSS  257/1042 143/509 1.24 (1.00-1.52) 221/943 142/504 1.33 (1.07-1.65) 217/933 180/613 1.40 (1.15-1.72)
MSI-H 
 
22/236 11/56 2.06 (0.93-4.52) 10/115 11/55 2.17 (0.89-5.31) 10/112 25/181 1.67 (0.77-3.61)
*Adjusted for age at diagnosis, sex, study population, body mass index, and history of cigarette smoking. All associations are relative to the KRAS wildtype case 
group.  All p-values for tests of interaction across strata indicate a lack of statistically significant interaction (p>0.05).
 
TABLE 3.  KRAS-mutation status and overall survival after colorectal cancer diagnosis by patient and tumor characteristics, with and 
without consideration of BRAF-mutation status 
  All cases BRAF-wildtype CRC only Joint KRAS / BRAF mutation status
  KRAS  
wildtype 
Deaths / 
Cases 
KRAS  
mutated
Deaths / 
Cases 
 
HR (95% CI)* 
KRAS  
wildtype
Deaths /
Cases 
KRAS  
mutated 
Deaths / 
Cases 
 
HR (95% CI)* 
 
KRAS & 
BRAF wt
Deaths / 
Cases 
 
KRAS or 
BRAF mut
Deaths / 
Cases 
 
HR (95% CI)* 
Overall (unadjusted) 487/1330 241/593 1.22 (1.05-1.43) 391/1098 239/587 1.28 (1.09-1.51) 386/1083 341/834 1.27 (1.10-1.47)
Overall (adjusted) 
 
487/1330 241/593 1.24 (1.06-1.45) 391/1098 239/587 1.27 (1.08-1.50) 386/1083 341/834 1.24 (1.07-1.44)
By age at 
diagnosis: 
<50 years 98/346 41/147 1.00 (0.70-1.45) 86/320 41/147 1.07 (0.74-1.55) 84/317 55/176 1.22 (0.87-1.72)
≥50 years 
 
389/984 200/446 1.31 (1.10-1.56) 305/778 198/440 1.33 (1.11-1.60) 293/766 286/658 1.24 (1.05-1.47)
By sex: Male 238/609 115/264 1.20 (0.96-1.50) 207/545 114/261 1.24 (0.98-1.56) 205/542 146/329 1.25 (1.00-1.55)
Female 
 
249/721 126/329 1.30 (1.04-1.61) 184/553 125/326 1.32 (1.05-1.67) 181/541 195/505 1.25 (1.01-1.53)
By tumor site: Proximal 195/505 109/255 1.21 (0.95-1.54) 121/322 107/252 1.24 (0.95-1.62) 120/315 185/444 1.13 (0.90-1.43)
Distal / rectal 
 
276/788 128/330 1.22 (0.99-1.51) 258/745 128/327 1.23 (0.99-1.53) 254/737 148/376 1.21 (0.99-1.49)
By stage at 
diagnosis: 
Localized 130/553 60/220 1.19 (0.87-1.63) 107/463 59/216 1.15 (0.83-1.59) 106/458 83/311 1.05 (0.78-1.42)
Regional 227/610 117/293 1.24 (0.99-1.55) 171/487 116/291 1.33 (1.05-1.69) 169/480 177/424 1.36 (1.09-1.68)
Distant 
 
118/144 62/75 1.01 (0.73-1.38) 104/129 62/75 1.05 (0.75-1.45) 102/126 76/90 1.09 (0.80-1.49)
By MSI: MSS  391/1042 213/509 1.21 (1.02-1.43) 344/943 212/504 1.26 (1.06-1.51) 340/933 261/613 1.28 (1.09-1.51)
MSI-H 
 
79/236 17/56 1.20 (0.68-2.12) 32/115 16/55 1.20 (0.63-2.30) 32/112 67/181 1.05 (0.67-1.64)
*Adjusted for age at diagnosis, sex, study population, body mass index, and history of cigarette smoking. All associations are relative to the KRAS wildtype case 
group.  All p-values for tests of interaction across strata indicate a lack of statistically significant interaction (p>0.05).
TABLE 4.  KRAS-mutation status, in combination with MSI and BRAF-mutation status, 
in relation to disease-specific and overall survival after colorectal cancer diagnosis 
 Disease-Specific Survival Overall Survival 
  
Deaths / Cases
 
HR (95% CI)* 
 
Deaths / Cases 
 
HR (95% CI)* 
Joint KRAS and MSI status    
  KRAS wt / MSI-H  22 / 236 0.35 (0.23-0.55) 79 / 236 0.78 (0.60-1.00) 
  KRAS mut / MSI-H 11 / 56 0.77 (0.42-1.41) 17 / 56 0.87 (0.53-1.42) 
  KRAS wt / MSS 257 / 1042 1.00 (ref) 391 / 1042 1.00 (ref) 
  KRAS mut / MSS  143 / 509 1.24 (1.01-1.52) 213 / 509 1.21 (1.02-1.43) 
     
Joint KRAS and MSI status (BRAF-wildtype only)   
  KRAS wt / MSI-H  10 / 112 0.34 (0.18-0.65) 32 / 112 0.74 (0.51-1.07) 
  KRAS mut / MSI-H 11 / 53 0.87 (0.47-1.60) 16 / 53 0.92 (0.55-1.52) 
  KRAS wt / MSS 217 / 933 1.00 (ref) 340 / 933 1.00 (ref) 
  KRAS mut / MSS  141 / 501 1.36 (1.09-1.68) 210 / 501 1.27 (1.07-1.52) 
     
Joint KRAS, BRAF, and MSI status    
  KRAS & BRAF wt / MSI-H  10 / 112 0.34 (0.18-0.65) 32 / 112 0.75 (0.52-1.08) 
  KRAS or BRAF mut / MSI-H 25 / 181 0.60 (0.39-0.91) 67 / 181 0.91 (0.69-1.20) 
  KRAS & BRAF wt / MSS 217 / 933 1.00 (ref) 340 / 933 1.00 (ref) 
  KRAS or BRAF mut / MSS  180 / 613 1.41 (1.15-1.73) 261 / 613 1.28 (1.08-1.51) 
* Adjusted for age at diagnosis, sex, study population, body mass index, and history of cigarette smoking.
 
 
 
